Substances Usage Disorder (SUD) is a type of mental disease that affects a person's brain and behaviours and makes it impossible for them to control how much alcohol, drugs, prescription medicine, or other substances they use. Addiction is the most extreme condition of SUDs, however, signs can range from mild to severe. According to research, around half of those who engage in SUDs will also experience a co-occurring mental condition at some point in their lives. Anxiety disorders, depression, media exposure behavioural disorders (ADHD), bipolar disorder, mental conditions, and schizophrenia are just a few examples of co-occurring disorders. Among other things, cognitive, emotional, and developmental variables make up psychological underpinnings. For instance, youths are more prone than adults to begin using alcohol or other substances and develop a substance use disorder. Other risk factors include being a man, being under 25, having other mental health issues (the latter two being linked to symptomatic relapse, impaired clinical and psychosocial adjustment, reduced medication adherence, and lower response to treatment), not having family support, and not having parental supervision.
Title : Tailoring biblio-poetry therapies using AI and biofeedback for addiction treatment
Nile Stanley, University of North Florida, United States
Title : The A-B-C of happiness coaching
Alphonsus Obayuwana, Triple-H Project LLC, United States
Title : Clinical pharmacology of marijuana: Update 2024
Frederick J Goldstein, Philadelphia College of Osteopathic Medicine, United States
Title : Trait-based recovery: Evidence-based trait activation to reduce depression, anxiety, and improve client engagement in addiction treatment
Jason Glenn Roop, The Center for Trait-Based Transformation, United States
Title : An investigation of the factors responsible for ubstance abuse from a cognitive perspective based on a mixed method approach
Adewole Olukorede, Literary Edifice, Italy
Title : A Long-Acting Naltrexone Implant (for Opioid Use Disorder: First-in-Human Phase I Trial)
Steven M Cohen, Akyso Therapeutics, United States